Central Nervous System (CNS) Therapeutic Market Analysis By Disease Type (Neurovascular Diseases, Trauma, Mental Health, Degenerative Disorder [Alzheimer's Diseases, Parkinson's Diseases, Multiple Sclerosis], Infections, Cancer), And Segment Forecasts, 2016 - 2025

Published: Jul, 2017 | Pages: 100 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global CNS therapeutic market is expected to reach USD 128.9 billion by 2025, according to a new report by Grand View Research, Inc. Rising prevalence of mental illnesses and increasing awareness regarding psychiatric disorders are driving market growth. In addition, expanding geriatric population and rising prevalence of lifestyle-associated CNS disorders are increasing global demand for CNS therapeutics.

Mental health segment accounted for the largest market share in 2016. It is expected to retain its dominance over the forecast period owing to developing therapeutic options for mental diseases such as personality disorders and binge eating disorders. This segment is followed by degenerative disorders segment. 

There is growing awareness regarding neurodegenerative diseases owing to increase in initiatives by government and nongovernment organizations, such as Alzheimer's and Related Disorders Society of India. These organizations conduct awareness campaigns and conferences, such as Asia Pacific Conference of ADI at New Delhi and Kerala State Initiative on Dementia, which encourage the adoption of treatment for degenerative and mental disorders.

Cancer segment is expected to emerge as the fastest growing segment in the Central Nervous System therapeutics market. High demand for effective treatment and a large number of drugs in later phases of clinical trials are factors expected to propel the growth of the segment.

Further key findings from the report suggest:

• Global mental health therapeutics revenue accounted for 48% share in 2016 and is expected to grow at a significant rate from 2016 to 2025

• Global demand for the treatment of Parkinson's and Alzheimer's diseases is anticipated to witness extensive growth over the next 9 years

• The industry in Asia Pacific is expected to report fastest growth over the forecast period owing to various developments across major economies of the region, especially in the mental health sector.

• Key players including Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Biogen, Inc.; Johnson & Johnson Services, Inc.; Eli Lilly and Company; and Novartis AG led the global CNS disease treatment market by capturing a majority share

 Table of Contents

Chapter 1 Research Methodology
                 1.1 Information Procurement
                 1.2 Data Analysis
                 1.3 Approaches for Market Estimation
                     1.3.1 Approach 1: Demand Analysis& Bottom up Approach
                     1.3.2 Approach 2: Top-down market estimation
                     1.3.3 Approach 3: Commodity flow and bottom up market estimation
                     1.3.4 Approach 4: KoL perspective based market sizing

Chapter 2 Executive Summary
                 2.1 Market Segmentation & Scope

Chapter 3 CNS Therapeutics Market Variables, Trends, & Scope
                 3.1 Market Segmentation & Scope
                     3.1.1 Market Driver Analysis
                         3.1.1.1 Increasing prevalence of CNS disorder
                         3.1.1.2 Patent cliff
                         3.1.1.3 Introduction of novel drug delivery system in CNS disorders
                     3.1.2 Market Restraint Analysis
                         3.1.2.1 High treatment cost
                 3.2 Penetration & Growth Prospect Mapping
                 3.3 CNS Therapeutics -SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
                 3.4 Industry Analysis - Porter's

Chapter 4 CNS Therapeutics Market: Disease Estimates & Trend Analysis
                 4.1 CNS Therapeutics Market: Disease Movement Analysis
                 4.2 Neurovascular Diseases
                     4.2.1 Neurovascular diseases market, 2014 - 2025 (USD Million)
                 4.3 Mental Health
                     4.3.1 Mental health market, 2014 - 2025 (USD Million)
                     4.3.2 Anxiety Disorders market, 2014 - 2025 (USD Million)
                         4.3.2.1 Anxiety disorder market, 2014 - 2025 (USD Million)
                     4.3.3 Mood Disorder
                         4.3.3.1 Mood disorder market, 2014 - 2025 (USD Million)
                     4.3.4 Substance Abuse Disorder
                         4.3.4.1 Substance abuse disorder market, 2014 - 2025 (USD Million)
                     4.3.5 Others (Attention Deficit, Personality, Insomnia, BED, etc.)
                         4.3.5.1 Others market, 2014 - 2025 (USD Million)
                 4.4 Degenerative Disorders
                     4.4.1 Degenerative disorders market, 2014 - 2025 (USD million)
                     4.4.2 Alzheimer's Disease
                         4.4.2.1 Alzheimer's Disease market, 2014 - 2025 (USD Million)
                     4.4.3 Parkinson's Disease
                         4.4.3.1 Parkinson's disease market, 2014 - 2025 (USD Million)
                     4.4.4 Multiple Sclerosis
                         4.4.4.1 Multiple sclerosis market, 2014 - 2025 (USD Million)
                     4.4.5 Others
                         4.4.5.1 Others market, 2014 - 2025 (USD Million)

Chapter 5 CNS Therapeutics Market: Regional Estimates & Trend Analysis, by Diseases
                 5.1 CNS Therapeutics : Region Movement Analysis
                 5.2 North America
                     5.2.1 North America CNS therapeutics market, 2014 - 2025 (USD Million)
                     5.2.2 U.S.
                         5.2.2.1 U.S. CNS therapeutics market, 2014 - 2025 (USD Million)
                     5.2.3 Canada
                         5.2.3.1 Canada CNS therapeutics market, 2014 - 2025 (USD Million)
                 5.3 Europe
                     5.3.1 Europe CNS therapeutics market, 2014 - 2025 (USD Million)
                     5.3.2 Germany
                         5.3.2.1 Germany CNS therapeutics market, 2014 - 2025 (USD Million)
                     5.3.3 UK
                         5.3.3.1 UK CNS therapeutics market, 2014 - 2025 (USD Million)
                 5.4 Asia Pacific
                     5.4.1 Asia Pacific CNS therapeutics market, 2014 - 2025 (USD Million)
                     5.4.2 China
                         5.4.2.1 China CNS therapeutics market, 2014 - 2025 (USD Million)
                     5.4.3 India
                         5.4.3.1 India CNS therapeutics market, 2014 - 2025 (USD Million)
                 5.5 Latin America
                     5.5.1 Latin America CNS therapeutics market, 2014 - 2025 (USD Million)
                     5.5.2 Brazil
                         5.5.2.1 Brazil CNS therapeutics market, 2014 - 2025 (USD Million)
                     5.5.3 Mexico
                         5.5.3.1 Mexico CNS therapeutics market, 2014 - 2025 (USD Million)
                 5.6 MEA
                     5.6.1 MEA CNS therapeutics market, 2014 - 2025 (USD Million)
                     5.6.2 South Africa
                         5.6.2.1 South Africa CNS therapeutics market, 2014 - 2025 (USD Million)

Chapter 6 Competitive Landscape
                 6.1 Market Participation Categorization
                 6.2 Company Profiles
                     6.2.1 Pfizer, Inc.
                         6.2.1.1 Company overview
                         6.2.1.2 Financial performance
                         6.2.1.3 Product benchmarking
                         6.2.1.4 Product pipelines
                         6.2.1.5 Strategic initiatives
                     6.2.2 Biogen, Inc.
                         6.2.2.1 Company overview
                         6.2.2.2 Financial performance
                         6.2.2.3 Product benchmarking
                         6.2.2.4 Product pipelines
                         6.2.2.5 Strategic initiatives
                     6.2.3 Otsuka Pharmaceutical Co., Ltd.
                         6.2.3.1 Company overview
                         6.2.3.2 Financial performance
                         6.2.3.3 Product benchmarking
                         6.2.3.4 Product pipelines
                         6.2.3.5 Strategic initiatives
                     6.2.4 Eli Lily
                         6.2.4.1 Company overview
                         6.2.4.2 Financial performance
                         6.2.4.3 Product benchmarking
                         6.2.4.4 Product pipelines
                         6.2.4.5 Strategic initiatives
                     6.2.5 Merck & Co.
                         6.2.5.1 Company overview
                         6.2.5.2 Financial performance
                         6.2.5.3 Product benchmarking
                         6.2.5.4 Product pipelines
                     6.2.6 Astra Zeneca
                         6.2.6.1 Company overview
                         6.2.6.2 Financial performance
                         6.2.6.3 Product benchmarking
                         6.2.6.4 Product pipelines
                     6.2.7 Shire PLC
                         6.2.7.1 Company overview
                         6.2.7.2 Financial performance
                         6.2.7.3 Product benchmarking
                         6.2.7.4 Product pipelines
                         6.2.7.5 Strategic initiatives
                     6.2.8 Novartis AG
                         6.2.8.1 Company overview
                         6.2.8.2 Financial performance
                         6.2.8.3 Product pipelines
                         6.2.8.4 Strategic initiatives
                     6.2.9 Teva Pharmaceuticals
                         6.2.9.1 Company overview
                         6.2.9.2 Financial performance
                         6.2.9.3 Product benchmarking
                         6.2.9.4 Product pipelines
                     6.2.10 Johnson & Johnson
                         6.2.10.1 Company overview
                         6.2.10.2 Financial performance
                         6.2.10.3 Product benchmarking
                         6.2.10.4 Strategic initiatives

List of Tables

TABLE 1 North America CNS therapeutics market
TABLE 2 North America mental health therapeutics market
TABLE 3 North America degenerative disease therapeutics market
TABLE 4 Canada CNS therapeutics market
TABLE 5 Canada mental health therapeutics market
TABLE 6 Canada degenerative disease therapeutics market
TABLE 7 Europe CNS therapeutics market
TABLE 8 Europe mental health therapeutics market
TABLE 9 Europe degenerative disease therapeutics market
TABLE 10 Germany CNS therapeutics market
TABLE 11 Germany mental health therapeutics market
TABLE 12 Germany degenerative disease therapeutics market
TABLE 13 UK CNS therapeutics market
TABLE 14 UK mental health therapeutics market
TABLE 15 UK degenerative disease therapeutics market
TABLE 16 Asia Pacific CNS therapeutics market
TABLE 17 Asia Pacific mental health therapeutics market
TABLE 18 Asia Pacific degenerative disease therapeutics market
TABLE 19 China CNS therapeutics market
TABLE 20 China mental health therapeutics market
TABLE 21 China degenerative disease therapeutics market
TABLE 22 India CNS therapeutics market
TABLE 23 India mental health therapeutics market
TABLE 24 India degenerative disease therapeutics market
TABLE 25 Latin America CNS therapeutics market
TABLE 26 Latin America mental health therapeutics market
TABLE 27 Latin America degenerative disease therapeutics market
TABLE 28 Brazil CNS therapeutics market
TABLE 29 Brazil mental health therapeutics market
TABLE 30 Brazil degenerative disease therapeutics market
TABLE 31 Mexico CNS therapeutics market
TABLE 32 Mexico mental health therapeutics market
TABLE 33 Mexico degenerative disease therapeutics market
TABLE 34 MEA CNS therapeutics market
TABLE 35 MEA mental health therapeutics market
TABLE 36 MEA degenerative disease therapeutics market
TABLE 37 South Africa CNS therapeutics market
TABLE 38 South Africa health therapeutics market
TABLE 39 South Africadegenerative disease therapeutics market